Dashboard
Manage Tickers

ARQT


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

fda-approves-arcutis-zoryve-cream-005-for-atopic-dermatitis-in-children-between-2-to-5
FDA Approves Arcutis' ZORYVE Cream 0.05% F...
10/06/2025 12:16:07

arcutis-to-present-new-zoryve-foam-cream-data-at-european-academy-of-dermatology-and-venereology-congress-in-paris
Arcutis To Present New ZORYVE Foam Cream D...
09/17/2025 08:38:25

arcutis-submits-snda-to-expand-zoryve-cream-use-for-plaque-psoriasis-in-children-as-young-as-2
Arcutis Submits sNDA To Expand ZORYVE Crea...
09/03/2025 15:47:15

If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as youn...

top-5-biotech-stocks-with-strong-momentum
Top 5 Biotech Stocks With Strong Momentum
08/28/2025 11:19:00

Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid rapid sector rallies.

needham-maintains-buy-on-arcutis-biotherapeutics-raises-price-target-to-22
Needham Maintains Buy on Arcutis Biotherap...
08/07/2025 10:34:01

Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $...

arcutis-biotherapeutics-q2-eps-013-beats-017-estimate-sales-81504m-beat-72753m-estimate
Arcutis Biotherapeutics Q2 EPS $(0.13) Bea...
08/06/2025 20:01:25

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate ...

Core News & Articles
Earnings Scheduled For August 6, 2025
08/06/2025 08:33:21

this-palantir-technologies-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-friday
This Palantir Technologies Analyst Begins ...
07/25/2025 12:34:15

goldman-sachs-initiates-coverage-on-arcutis-biotherapeutics-with-neutral-rating-announces-price-target-of-18
Goldman Sachs Initiates Coverage On Arcuti...
07/25/2025 10:59:53

Goldman Sachs analyst Richard Law initiates coverage on Arcutis Biotherapeutics (NASDAQ:ARQT) with a Neutral rating and ann...

arcutis-biotherapeutics-zoryve-cream-015-received-recommendation-in-focused-guideline-update-for-management-of-adult-ad-from-aad
Arcutis Biotherapeutics' ZORYVE cream 0.15...
06/26/2025 12:08:55

The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.1...

arcutis-biotherapeutics-enrolls-first-child-in-phase-2-open-label-study-integument-infant-evaluating-safety-and-tolerability-of-investigational-zoryve-cream-005-in-infants-with-ad-applied-once-daily-over-a-four-week-period
Arcutis Biotherapeutics Enrolls First Chil...
06/10/2025 12:14:09

Four-week Phase 2 study to evaluate investigational, once-daily ZORYVE .05% in infants as young as 3 months to less than 2 year...

arcutis-unveils-long-term-efficacy-safety-for-zoryve-cream-in-pediatric-patients-with-atopic-dermatitis
Arcutis Unveils Long-Term Efficacy, Safety...
06/06/2025 15:11:50

Arcutis will present five posters at RAD 2025 featuring long-term safety and efficacy data for Zoryve cream in children with ec...

arcutis-says-new-data-from-phase-3-integument-ole-long-term-open-label-study-show-durable-improvement-in-signs-and-symptoms-of-atopic-dermatitis
Arcutis Says New Data From Phase 3 INTEGUM...
06/06/2025 12:03:35

arcutis-to-present-new-long-term-results-of-zoryve-cream-at-2025-revolutionizing-atopic-dermatitis-conference
Arcutis To Present New Long-Term Results O...
06/06/2025 12:03:06

New data from the Phase 3 INTEGUMENT-OLE long-term open label study show durable improvement in the signs and symptoms of atopi...

analyst-expectations-for-arcutis-biotherapeuticss-future
Analyst Expectations For Arcutis Biotherap...
05/23/2025 12:01:28

needham-reiterates-buy-on-arcutis-biotherapeutics-maintains-20-price-target
Needham Reiterates Buy on Arcutis Biothera...
05/23/2025 09:57:09

Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $20 price target.

arcutis-biotherapeutics-gains-fda-nod-for-snda-for-zoryve-topical-foam-03-for-plaque-psoriasis-treatment
Arcutis Biotherapeutics Gains FDA Nod For ...
05/22/2025 18:17:23

Once-daily ZORYVE foam provides powerful clearance and rapid itch relief from head to toe with no limitation on duration of use...

arcutis-biotherapeutics-says-zoryve-foam-03-linked-to-adverse-reactions-including-headache-nausea-and-diarrhea-with-flammability-risk-and-contraindications-for-liver-impaired-patients-highlighted-in-safety-profile-under-fda-review
Arcutis Biotherapeutics Says ZORYVE Foam 0...
05/07/2025 15:32:16

IMPORTANT SAFETY INFORMATIONZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C)....

arcutis-biotherapeutics-publishes-results-from-pivotal-phase-3-study-evaluating-efficacy-and-safety-of-zoryve-foam-03-as-once-daily-monotherapy-treatment-for-psoriasis-in-jama-dermatology
Arcutis Biotherapeutics Publishes Results ...
05/07/2025 15:20:59

Once-daily, investigational ZORYVE foam 0.3%, rapidly improved psoriasis of the scalp and body, including itch, when used as a ...

arcutis-biotherapeutics-q1-eps-020-beats-021-estimate-sales-6585m-beat-6225m-estimate
Arcutis Biotherapeutics Q1 EPS $(0.20) Bea...
05/06/2025 20:03:43

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION